Abstract
Introduction: The anthracycline doxorubicin (DOX) has proved to be one of the most widely used and most effective antitumor drugs since its emergence in the 1960s. However, the utility of DOX is compromised by its potential lethal cardiotoxicity. In this review we summarize development in prevention and management of DOX-induced cardiotoxicity comprehensively.
Background: Strategies to enhance DOX efficacy in cancer cells while minimizing associated cardiotoxicity may prove clinically valuable. Employment of DOX derivatives, including currently available mitoxantrone and epirubicin, has been testified in several clinical trials. Several cardioprotective agents, including dexrazoxane, statins, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and etc., have been developed and tested in animal and clinical trials.
Conclusion: Several strategies have been reported on the prevention and management of DOX-elicited cardiotoxicity, and many of them await verification from large scale clinical trials. Dexrazoxane has been approved to prevent and treat side effects of DOX, although concerns still exist that it might increase incidence of some kind of malignant tumors. Promising findings in autophagy, RNA binding protein quaking and statins encourage further research developing strategies by which heart protection and cancer cell killing are achieved simutaneously.
Keywords: Cardiotoxicity, doxorubicin, RNA-binding protein Quaking, statins.
Mini-Reviews in Medicinal Chemistry
Title:Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Volume: 17 Issue: 1
Author(s): Hao Liu, Haiyan Wang, Dingcheng Xiang and Wangang Guo
Affiliation:
Keywords: Cardiotoxicity, doxorubicin, RNA-binding protein Quaking, statins.
Abstract: Introduction: The anthracycline doxorubicin (DOX) has proved to be one of the most widely used and most effective antitumor drugs since its emergence in the 1960s. However, the utility of DOX is compromised by its potential lethal cardiotoxicity. In this review we summarize development in prevention and management of DOX-induced cardiotoxicity comprehensively.
Background: Strategies to enhance DOX efficacy in cancer cells while minimizing associated cardiotoxicity may prove clinically valuable. Employment of DOX derivatives, including currently available mitoxantrone and epirubicin, has been testified in several clinical trials. Several cardioprotective agents, including dexrazoxane, statins, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and etc., have been developed and tested in animal and clinical trials.
Conclusion: Several strategies have been reported on the prevention and management of DOX-elicited cardiotoxicity, and many of them await verification from large scale clinical trials. Dexrazoxane has been approved to prevent and treat side effects of DOX, although concerns still exist that it might increase incidence of some kind of malignant tumors. Promising findings in autophagy, RNA binding protein quaking and statins encourage further research developing strategies by which heart protection and cancer cell killing are achieved simutaneously.
Export Options
About this article
Cite this article as:
Liu Hao, Wang Haiyan, Xiang Dingcheng and Guo Wangang, Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity, Mini-Reviews in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1389557516666160621083659
DOI https://dx.doi.org/10.2174/1389557516666160621083659 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Importance of Lost Minerals in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Apoptosis and Oxidative Stress-Related Diseases: The p66Shc Connection
Current Molecular Medicine TTR Fibril Formation Inhibitors: Is there a SAR?
Current Medicinal Chemistry Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry Patent Selections
Recent Patents on Regenerative Medicine Engineering Three-Dimensional Cardiac Microtissues for Potential Drug Screening Applications
Current Medicinal Chemistry The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals GLP - 1 Analogs: Newer Molecules, Newer Uses
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Fluctuations of Melatonin and Copeptin Levels in Blood Serum During Surgical Stress Regarding the Pediatric Population
Current Pediatric Reviews Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Proteome and Metabolome Alterations in Heart and Liver Indicate Compromised Energy Production During Sepsis
Protein & Peptide Letters Human Heart Failure: A Proteomics Perspective
Current Proteomics Light Chain Amyloidosis – Current Findings and Future Prospects
Current Protein & Peptide Science A beta oligomerization A Therapeutic Target for Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents